Fiasp is an ultra-rapid-acting mealtime insulin designed to work faster than standard rapid-acting insulins. It contains the same active ingredient as NovoLog (insulin aspart) but is reformulated with two key additives, niacinamide and L-arginine, that speed up how quickly the insulin gets absorbed into your bloodstream. The result is an insulin you can take right when you sit down to eat, or even up to 20 minutes after you start your meal.
How Fiasp Differs From Standard Rapid-Acting Insulin
Standard rapid-acting insulins like NovoLog, Humalog, and Apidra typically begin working within 10 to 30 minutes, peak between 45 and 75 minutes, and last roughly 3 to 5 hours. These insulins work well, but most people need to inject them 10 to 15 minutes before a meal to catch the blood sugar spike that comes with eating. That timing requirement can be inconvenient and easy to forget.
Fiasp closes that gap. The niacinamide (a form of vitamin B3) in the formula helps insulin aspart absorb into the bloodstream more quickly after injection. L-arginine acts as a stabilizer to keep the formulation shelf-stable. This faster absorption means you can inject at the start of a meal rather than planning ahead, and the insulin reaches your blood sooner to match the rise in glucose from food.
The only other insulin in this ultra-rapid category is Lyumjev, which uses a different approach to speed absorption. Lyumjev is a reformulated version of insulin lispro (the active ingredient in Humalog) and uses treprostinil and citrate instead of niacinamide. Both Fiasp and Lyumjev aim to solve the same problem: getting mealtime insulin to act more like the quick burst of insulin a healthy pancreas releases when you eat.
When and How to Take It
The FDA-approved dosing window for Fiasp is at the start of a meal or within 20 minutes after you begin eating. That post-meal flexibility is one of its biggest practical advantages. If you’re someone who doesn’t always know what or how much you’ll eat, being able to dose during or shortly after a meal gives you more control over how much insulin you take relative to what you actually consumed.
Fiasp can be injected subcutaneously into the abdomen, upper arm, or thigh. It’s also approved for use in insulin pumps for continuous subcutaneous infusion. Each milliliter contains 100 units of insulin aspart, the same concentration as standard NovoLog, so converting between the two doesn’t require a dose change. Your total dose is based on the same factors as any mealtime insulin: the amount of carbohydrates you’re eating, your current blood sugar, and your individual insulin sensitivity.
What’s Actually in the Formulation
Beyond the insulin aspart itself, each milliliter of Fiasp contains 20.8 mg of niacinamide (the absorption accelerator), 3.48 mg of L-arginine hydrochloride (the stabilizer), along with standard insulin excipients like glycerin, zinc, phenol, and metacresol. The pH is adjusted to 7.1, which is close to the natural pH of your body’s tissues. The niacinamide dose is small enough that it doesn’t produce the flushing sometimes associated with niacin supplements.
Storage and Shelf Life
Unopened Fiasp vials and pens should be stored in the refrigerator. Once you start using a vial or pen, it can be kept at room temperature (between 59°F and 86°F) for up to 28 days. After that, discard it even if there’s insulin remaining. If you use Fiasp in an insulin pump, the insulin in the reservoir, tubing, and infusion set should be replaced every 48 hours. Heat and direct sunlight degrade insulin, so avoid leaving pens in a hot car or near a window.
Who Fiasp Is For
Fiasp is approved for adults with type 1 or type 2 diabetes who need mealtime insulin. For people with type 1, it’s used alongside a long-acting basal insulin or in a pump. For people with type 2, it can be added when basal insulin alone isn’t controlling post-meal blood sugar spikes well enough.
The faster onset makes Fiasp particularly useful for people who struggle with the timing of traditional rapid-acting insulin. If you frequently forget to pre-bolus, or if you have unpredictable eating schedules, the ability to dose at the table or shortly after can reduce the mismatch between when insulin peaks and when your blood sugar rises. It’s also a common choice for people using closed-loop insulin pump systems, where faster insulin action helps the algorithm respond to blood sugar changes more quickly.
Side Effects and Practical Considerations
The side effect profile is essentially the same as standard insulin aspart. Hypoglycemia (low blood sugar) is the most common risk, especially if you take too much relative to the carbohydrates you eat or if you exercise after dosing. Injection site reactions like redness, swelling, or itching can occur but are generally mild.
Some pump users have reported more frequent infusion site irritation with Fiasp compared to standard insulin aspart. If you notice redness, pain, or hardness at your infusion site, rotating sites more frequently or switching to a different insulin may help. Occlusion alarms (where the pump detects a blockage) have also been reported more often with Fiasp in pumps, so it’s worth paying attention to how your sites respond during the first few weeks.
Because Fiasp acts faster, it also leaves your system a bit sooner than traditional rapid-acting insulin. This can be an advantage (less “insulin stacking” between meals) but also means you may see blood sugar rise slightly earlier at the tail end of its action, particularly after high-fat or high-protein meals that digest slowly. Many people adjust by splitting their dose or using an extended bolus feature on their pump for those types of meals.